Poly(ADP-ribose) polymerase-1 mRNA expression in human breast cancer: a meta-analysis - PubMed (original) (raw)

Meta-Analysis

. 2011 May;127(1):273-81.

doi: 10.1007/s10549-010-1199-y. Epub 2010 Nov 11.

Affiliations

Meta-Analysis

Poly(ADP-ribose) polymerase-1 mRNA expression in human breast cancer: a meta-analysis

Anthony Gonçalves et al. Breast Cancer Res Treat. 2011 May.

Abstract

Although poly(ADP-ribose) polymerase-1 (PARP1) inhibition is a recent promising therapy in breast cancer, PARP1 expression in this disease is not known. Using DNA microarray and array-based comparative genomic hybridization (arrayCGH), we examined PARP1 mRNA expression and copy number alterations in 326 invasive breast cancer samples and normal breast (NB) samples. A meta-analysis was performed on a large public retrospective gene expression data set (n = 2,485) to analyze correlation between PARP1 mRNA expression and molecular subtypes and clinico-pathological parameters. PARP1 was overexpressed in 58% of cancers, and its expression was heterogeneous between tumors. ArrayCGH data revealed an association between mRNA overexpression and gain/amplification at the PARP1 locus (P < 1.0E-8). Meta-analysis showed that PARP1 expression was higher in basal breast cancers (P < 1.0E-72), but overexpression was also found in other subtypes. PARP1 expression correlated with high grade, medullary histological type, tumor size, and worse metastasis-free survival (MFS; HR = 1.12 [1.04-1.22], P = 0.004) and overall survival (OS; HR = 1.16 [1.04-1.29], P = 0.006). In multivariate analysis, PARP1 expression had an independent prognostic value for MFS, which was restricted to patients untreated with any adjuvant chemotherapy. These data demonstrate overexpression of PARP1 in a large number of breast cancers and support the development of PARP inhibitors in basal subtype, but also potentially in other breast cancer subtypes.

PubMed Disclaimer

Comment in

Publication types

MeSH terms

Substances

LinkOut - more resources